<p>/PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM)（以下簡稱 “公司”）今天宣佈，其董事會（以下簡稱 “董事會”）已批准，公司打算自納斯達克證券市場（“納斯達克”）自願退市，並註銷其普通股，以暫停並最終終止公司根據 1934 年證券交易法（修訂版）（“交易法”）的報告義務。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1219543/Carisma_Therapeutics_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1219543/Carisma_Therapeutics_Logo.jpg"/></p>
<p>如之前所述，由於公司之前披露的未能遵守納斯達克上市規則 5450(a)(1)、5450(b)(2)(C) 和 5450(b)(2)(A) 中規定的最低報價、上市證券的市場價值和公眾持有股份的市場價值要求，公司於 2025 年 10 月 9 日收到了納斯達克的退市決定函（“決定函”），並且公司的普通股自 2025 年 10 月 13 日起暫停在納斯達克交易。公司的普通股於 2025 年 10 月 13 日在 OTCID 市場層級開始交易，交易代碼為 “CARM”。</p>
<p>決定函指出，一旦所有適用的上訴期限屆滿，納斯達克將向證券交易委員會（“SEC”）提交一份 25 號表格，以完成公司普通股從納斯達克的退市。儘管如此，公司今天通知納斯達克，其打算自願退市，而不是等待納斯達克在稍後的日期提交 25 號表格。公司預計將在 2025 年 12 月 15 日左右向 SEC 提交 25 號表格，以實施普通股的退市和註銷，並且公司的普通股從納斯達克的正式退市預計將在 2025 年 12 月 25 日左右生效。</p>
<p>在公司普通股從納斯達克退市後，公司打算向 SEC 提交 15 號表格，以暫停並最終終止其根據交易法的報告義務。公司將在註銷生效後解除所有根據交易法的報告義務。公司預計其普通股的註銷將在向 SEC 提交 15 號表格後 90 天生效。提交給 SEC 的文件將在公司網站上提供，網址為 https://carismatx.com/。</p>
<p>董事會在仔細考慮多個因素後決定加速普通股的退市和註銷，包括收到納斯達克的決定函、納斯達克預計將按時提交 25 號表格，以及公司正在持續進行有序結束其運營的努力。</p>
<p><strong>關於 Carisma Therapeutics</strong></p>
<p>Carisma Therapeutics 是一家生物技術公司，之前專注於利用其在巨噬細胞工程方面的行業領先專業知識，開發變革性療法以治療包括肝纖維化和癌症在內的嚴重疾病。Carisma 總部位於賓夕法尼亞州費城。</p>
<p><strong>關於前瞻性聲明的警示説明</strong></p>
<p>本新聞稿包含 1995 年《私人證券訴訟改革法》所定義的前瞻性聲明，包括但不限於關於從納斯達克退市和公司普通股註銷的預期時間、公司保持現金以充分資助公司運營有序結束的能力，以及公司為最大化其現金狀況以惠及利益相關者所採取的行動的聲明。&#34;預計&#34;、&#34;相信&#34;、&#34;繼續&#34;、&#34;可能&#34;、&#34;估計&#34;、&#34;期待&#34;、&#34;希望&#34;、&#34;打算&#34;、&#34;可能&#34;、&#34;計劃&#34;、&#34;潛在&#34;、&#34;預測&#34;、&#34;項目&#34;、&#34;目標&#34;、&#34;應該&#34;、&#34;會&#34;及類似表達旨在識別前瞻性聲明，儘管並非所有前瞻性聲明都包含這些識別詞。實際結果或事件可能因各種重要因素而與這些前瞻性聲明中披露的計劃、意圖和預期大相徑庭，包括在 Carisma 截至 2024 年 12 月 31 日的年度報告的 “風險因素” 標題下描述的風險，該報告最初於 2025 年 3 月 31 日向 SEC 提交，並由 2025 年 4 月 29 日向 SEC 提交的年度報告修正案第 1 號修正，以及隨後向 SEC 提交的季度報告，每份報告均已向 SEC 備案，以及公司未來可能向 SEC 提交的其他文件中描述的風險。除法律另有要求外，公司不承擔更新或修訂任何前瞻性聲明以反映該聲明日期後事件或情況的義務。</p>
<p><strong>聯繫方式</strong>：</p>
<p>Steven Kelly</p>
<p>steven.kelly@carismatx.com</p>
<p>來源：Carisma Therapeutics Inc.</p>

CARM

<p>Carisma Therapeutics Inc. 宣佈自願從納斯達克退市，並向美國證券交易委員會（SEC）申請註銷，以終止其報告義務。此決定是由於未遵守納斯達克上市規則而作出的退市決定。該公司的股票將轉在 OTCID 市場交易。退市預計將在 2025 年 12 月 25 日生效，註銷將在提交 Form 15 後 90 天生效。Carisma 旨在保留現金，以便有序結束運營</p>

<p>, /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the &#34;Company&#34;) today announced that its Board of Directors (the &#34;Board&#34;) has approved and the Company intends to proceed with the voluntary delisting of its common stock from The Nasdaq Stock Market LLC (&#34;Nasdaq&#34;) and the deregistration of its common stock in order to suspend and ultimately terminate the Company's reporting obligations under the Securities and Exchange Act of 1934, as amended (the &#34;Exchange Act&#34;).</p>
<div class="lb-trans"><p>/PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM)（以下簡稱 “公司”）今天宣佈，其董事會（以下簡稱 “董事會”）已批准，公司打算自納斯達克證券市場（“納斯達克”）自願退市，並註銷其普通股，以暫停並最終終止公司根據 1934 年證券交易法（修訂版）（“交易法”）的報告義務。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1219543/Carisma_Therapeutics_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/1219543/Carisma_Therapeutics_Logo.jpg"/></p>
<p>As previously reported, as a result of the Company's previously disclosed noncompliance with the bid price, market value of listed securities, and market value of publicly held shares requirements set forth in Nasdaq Listing Rules 5450(a)(1), 5450(b)(2)(C), and 5450(b)(2)(A), respectively, the Company received a delist determination letter from Nasdaq on October 9, 2025 (the &#34;Determination Letter&#34;) and the Company's common stock was suspended from trading on Nasdaq effective at the open of business on October 13, 2025. The Company's common stock commenced trading on the OTCID market tier operated by the OTC Markets Group on October 13, 2025, under the trading symbol &#34;CARM.&#34;</p>
<div class="lb-trans"><p>如之前所述，由於公司之前披露的未能遵守納斯達克上市規則 5450(a)(1)、5450(b)(2)(C) 和 5450(b)(2)(A) 中規定的最低報價、上市證券的市場價值和公眾持有股份的市場價值要求，公司於 2025 年 10 月 9 日收到了納斯達克的退市決定函（“決定函”），並且公司的普通股自 2025 年 10 月 13 日起暫停在納斯達克交易。公司的普通股於 2025 年 10 月 13 日在 OTCID 市場層級開始交易，交易代碼為 “CARM”。</p>
</div><p>The Determination Letter indicated that, once all applicable appeal periods had lapsed, Nasdaq would file a Form 25 with the Securities and Exchange Commission (the &#34;SEC&#34;) to complete the delisting of the Company's common stock from Nasdaq. Notwithstanding, the Company today notified Nasdaq of its intention to voluntarily delist its shares of common stock from Nasdaq rather than await Nasdaq's filing of a Form 25 at some later date. The Company anticipates that it will file a Form 25 with the SEC to effect the delisting and deregistration of its common stock on or about December 15, 2025 and that the formal delisting of the Company's common stock from Nasdaq will become effective on or about December 25, 2025.</p>
<div class="lb-trans"><p>決定函指出，一旦所有適用的上訴期限屆滿，納斯達克將向證券交易委員會（“SEC”）提交一份 25 號表格，以完成公司普通股從納斯達克的退市。儘管如此，公司今天通知納斯達克，其打算自願退市，而不是等待納斯達克在稍後的日期提交 25 號表格。公司預計將在 2025 年 12 月 15 日左右向 SEC 提交 25 號表格，以實施普通股的退市和註銷，並且公司的普通股從納斯達克的正式退市預計將在 2025 年 12 月 25 日左右生效。</p>
</div><p>Following the delisting of the Company's common stock from Nasdaq, the Company intends to file a Form 15 with the SEC to suspend and then terminate its reporting obligations under the Exchange Act. The Company will be relieved of all reporting obligations under the Exchange Act upon the effectiveness of the deregistration. The Company expects that the deregistration of its common stock will become effective 90 days after the filing of the Form 15 with the SEC. The documents filed with the SEC will be available on the Company's website at https://carismatx.com/.</p>
<div class="lb-trans"><p>在公司普通股從納斯達克退市後，公司打算向 SEC 提交 15 號表格，以暫停並最終終止其根據交易法的報告義務。公司將在註銷生效後解除所有根據交易法的報告義務。公司預計其普通股的註銷將在向 SEC 提交 15 號表格後 90 天生效。提交給 SEC 的文件將在公司網站上提供，網址為 https://carismatx.com/。</p>
</div><p>The Board determined to accelerate the delisting and deregistration of its common stock after careful consideration of numerous factors, including receipt of the Determination Letter from Nasdaq, the expected filing in due course of a Form 25 by Nasdaq, and the Company's ongoing pursuit of an orderly wind down of its operations.</p>
<div class="lb-trans"><p>董事會在仔細考慮多個因素後決定加速普通股的退市和註銷，包括收到納斯達克的決定函、納斯達克預計將按時提交 25 號表格，以及公司正在持續進行有序結束其運營的努力。</p>
</div><p><strong>About Carisma Therapeutics</strong></p>
<div class="lb-trans"><p><strong>關於 Carisma Therapeutics</strong></p>
</div><p>Carisma Therapeutics is a biotechnology company that was previously focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. Carisma is headquartered in Philadelphia, PA.</p>
<div class="lb-trans"><p>Carisma Therapeutics 是一家生物技術公司，之前專注於利用其在巨噬細胞工程方面的行業領先專業知識，開發變革性療法以治療包括肝纖維化和癌症在內的嚴重疾病。Carisma 總部位於賓夕法尼亞州費城。</p>
</div><p><strong>Cautionary Note Regarding Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示説明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the expected timing of the delisting from Nasdaq and deregistration of the Company's common stock, the Company's ability to preserve cash in order to adequately fund an orderly wind down of the Company's operations, and the Company's actions to maximize the Company's cash position for the benefit of its stakeholders. The words &#34;anticipate,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;hope,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;target,&#34; &#34;should,&#34; &#34;would,&#34; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including those risks described under the caption &#34;Risk Factors&#34; in Carisma's Annual Report on Form 10-K for the year ended December 31, 2024, which was originally filed with the SEC on March 31, 2025, as amended by Amendment No. 1 to the Annual Report on Form 10-K/A, which was filed with the SEC on April 29, 2025 and subsequent Quarterly Reports on Form 10-Q filed with the SEC, each of which is on file with the SEC, and risks described in other filings that the Company may make with the SEC in the future. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect events or circumstances after the date of such statements for any reason, except as otherwise required by law.</p>
<div class="lb-trans"><p>本新聞稿包含 1995 年《私人證券訴訟改革法》所定義的前瞻性聲明，包括但不限於關於從納斯達克退市和公司普通股註銷的預期時間、公司保持現金以充分資助公司運營有序結束的能力，以及公司為最大化其現金狀況以惠及利益相關者所採取的行動的聲明。&#34;預計&#34;、&#34;相信&#34;、&#34;繼續&#34;、&#34;可能&#34;、&#34;估計&#34;、&#34;期待&#34;、&#34;希望&#34;、&#34;打算&#34;、&#34;可能&#34;、&#34;計劃&#34;、&#34;潛在&#34;、&#34;預測&#34;、&#34;項目&#34;、&#34;目標&#34;、&#34;應該&#34;、&#34;會&#34;及類似表達旨在識別前瞻性聲明，儘管並非所有前瞻性聲明都包含這些識別詞。實際結果或事件可能因各種重要因素而與這些前瞻性聲明中披露的計劃、意圖和預期大相徑庭，包括在 Carisma 截至 2024 年 12 月 31 日的年度報告的 “風險因素” 標題下描述的風險，該報告最初於 2025 年 3 月 31 日向 SEC 提交，並由 2025 年 4 月 29 日向 SEC 提交的年度報告修正案第 1 號修正，以及隨後向 SEC 提交的季度報告，每份報告均已向 SEC 備案，以及公司未來可能向 SEC 提交的其他文件中描述的風險。除法律另有要求外，公司不承擔更新或修訂任何前瞻性聲明以反映該聲明日期後事件或情況的義務。</p>
</div><p><strong>Contact</strong>:</p>
<div class="lb-trans"><p><strong>聯繫方式</strong>：</p>
</div><p>Steven Kelly</p>
<div class="lb-trans"><p>Steven Kelly</p>
</div><p>steven.kelly@carismatx.com</p>
<div class="lb-trans"><p>steven.kelly@carismatx.com</p>
</div><p>SOURCE Carisma Therapeutics Inc.</p>
<div class="lb-trans"><p>來源：Carisma Therapeutics Inc.</p>
</div>

Carisma 宣佈從納斯達克退市並註銷美國證券交易委員會登記 | CARM 股票新聞